Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiko Pharmaceutical CoTSE:4574 +0.37%64 EV-to-EBIT is 21.20 as of Aug. 25, 2026, which is 85% above its 10-year median of 11.48. GuruFocus rates TSE:4574 with a GF Score™ of 64/100 and a GF Value™ of 円262.53 (Fairly Valued). The stock has 4 warning signs investors should review. Among 690 Drug Manufacturers companies, Taiko Pharmaceutical Co ranks worse than 60.29% on this metric.
Taiko Pharmaceutical Co (TSE:4574) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Taiko Pharmaceutical Co's Enterprise Value for the quarter that ended in Jun. 2026 was 円11,306 Mil.
Taiko Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円500 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiko Pharmaceutical Co EV-to-EBIT Related Terms
Taiko Pharmaceutical Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Taiko Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiko Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Taiko Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Taiko Pharmaceutical Co's EV-to-EBIT falls into.
Taiko Pharmaceutical Co's current Enterprise Value is 円10,602 Mil.
Taiko Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円500 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiko Pharmaceutical Co (TSE:4574) has a EV-to-EBIT of 21.20 as of Aug. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Taiko Pharmaceutical Co and its competitors. This is 85% above median its historical median of 11.48. According to the industry distribution chart, Taiko Pharmaceutical Co ranks #416 out of 690 companies in the Drug Manufacturers industry, placing it in the top 60.3%.
Is Taiko Pharmaceutical Co's EV-to-EBIT too high?
Taiko Pharmaceutical Co's current EV-to-EBIT of 21.20 is 85% above median its 10-year median of 11.48. The Drug Manufacturers industry median EV-to-EBIT is 15.81. Taiko Pharmaceutical Co's value of 21.20 is 34.1% above this industry median. Based on the distribution chart, Taiko Pharmaceutical Co ranks #416 out of 690 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Taiko Pharmaceutical Co has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiko Pharmaceutical Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Taiko Pharmaceutical Co ranks #416 out of 690 companies for EV-to-EBIT. This places Taiko Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBIT is 15.81. Taiko Pharmaceutical Co's value of 21.20 is 34.1% above this benchmark. While the company's 10-year median is 11.48 vs. the industry median of 15.81, Taiko Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.81, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiko Pharmaceutical Co's current EV-to-EBIT of 21.20 is 34.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Taiko Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiko Pharmaceutical Co's current EV-to-EBIT is 21.20, which is 85% above median its own 10-year median of 11.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiko Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Taiko Pharmaceutical Co (TSE:4574) is currently considered Fairly Valued. The stock's GF Value™ is 円262.53, compared to a current price of 円269.00 — trading 2.5% above its estimated fair value. The current EV-to-EBIT is 21.20, which is 85% above median its 10-year median of 11.48 and 34.1% above the Drug Manufacturers industry median of 15.81. Taiko Pharmaceutical Co's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Taiko Pharmaceutical Co (TSE:4574), the current EV-to-EBIT is 21.20 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiko Pharmaceutical Co (TSE:4574) Overvalued in 2026?
Based on GuruFocus' analysis, Taiko Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円269.00 is trading 2.5% above its estimated GF Value™ of 円262.53.
GuruFocus considers Taiko Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4574:
EV-to-EBIT: 21.20 (85% above median its 10-year median of 11.48)
GF Value™: 円262.53 vs. price of 円269.00 (2.5% above fair value)
Industry Position: 34.1% above the Drug Manufacturers median (#416 of 690)
No single metric tells the full story. See the TSE:4574 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.
64GF Score
Get the complete analysis for TSE:4574
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4574 has been successfully added to your 
